15 years Biosimilars
Biosimilars are an important part of the effective biological treatments available in the EU. This makes it possible to relieve the financial burden on the healthcare system and to make important therapies accessible to a wider range of patients.
Fifteen years ago, the world’s first biosimilar was approved by the European Commission in Europe, and it came from Austria to boot. Thanks to the pioneering role of the European Medicines Agency (EMA) in developing its own regulatory pathway, 67 biosimilars for 16 active substances are now approved and on the market in Europe. In Austria, 45 biosimilars for 15 active ingredients are currently available.